5 Key Takeaways
-
1
Axplora is investing millions to expand lyophilization capabilities at its Le Mans site to enhance ADC manufacturing.
-
2
The investment aims to improve control, speed, and predictability in ADC development and supply for biotech customers.
-
3
New commercial lyophilization capabilities will be operational by early 2027, complementing existing R&D facilities.
-
4
François Houbart has been appointed as Head of Site, focusing on operational excellence and quality in ADC programs.
-
5
The expansion is part of a €30m multi-year investment program to support the growth of ADC pipelines globally.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
